Allogeneic ‘off‐the‐shelf’ <scp>SARS</scp>‐<scp>C</scp>o<scp>V</scp>‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease

Andrea Henden(The University of Queensland), Corey Smith(QIMR Berghofer Medical Research Institute), Srividhya Swaminathan(The University of Queensland), Arushi Mahajan(QIMR Berghofer Medical Research Institute), Matthew D. Solomon(Sutter Health), Siok‐Keen Tey(The University of Queensland), Katie E. Lineburg(QIMR Berghofer Medical Research Institute), Glen Kennedy(Royal Brisbane and Women's Hospital), Ricky Nelles(Royal Brisbane and Women's Hospital), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Archana Panikkar(QIMR Berghofer Medical Research Institute), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Shannon E. Best(QIMR Berghofer Medical Research Institute), E. H. M. Wright(Royal Brisbane and Women's Hospital), Hilary Reddiex(QIMR Berghofer Medical Research Institute), Laëtitia Le Texier(QIMR Berghofer Medical Research Institute), Leone Beagley, Jyothy Raju(QIMR Berghofer Medical Research Institute), Pauline Crooks(QIMR Berghofer Medical Research Institute)
Clinical & Translational Immunology
January 1, 2025
Cited by 1


Related Papers